8-K - Replimune Group, Inc. | StockGist

Current Report Details

Event Type

Regulation Fd

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, a

Regulation Fd

8.01

Other Events . On September 16, 2025, the Company completed a Type A meeting with the FDA regarding the Company’s BLA for RP1 in combination with nivolumab for

Other Event

9.01

Financial Statements and Exhibits . Exhibit No. Description 99.1 News Release dated September 18, 2025 104 Cover page interactive data file (formatted as Inline

Exhibits Only

Source Document

Exhibits (2)

8-K

FORM 8-K

99.1

EXHIBIT 99.1